Aspire Biopharma Holdings, Inc.
ASBP
$1.06
-$0.14-11.67%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 302.78% | 433.39% | 459.34% | 381.70% | 279.03% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 331.60% | 552.17% | 561.72% | 419.35% | 255.62% |
| Operating Income | -331.08% | -551.86% | -561.72% | -419.35% | -255.62% |
| Income Before Tax | -1,770.33% | -3,215.38% | -3,924.61% | -3,575.06% | -284.41% |
| Income Tax Expenses | -- | -100.00% | 100.00% | 100.00% | 100.00% |
| Earnings from Continuing Operations | -1,768.91% | -3,207.38% | -3,920.54% | -3,571.31% | -284.13% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1,768.91% | -3,207.38% | -3,920.54% | -3,571.31% | -284.13% |
| EBIT | -331.08% | -551.86% | -561.72% | -419.35% | -255.62% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -1,046.94% | -2,567.30% | -4,077.22% | -5,391.97% | -949,050.00% |
| Normalized Basic EPS | -245.76% | -639.99% | -876.91% | -937.12% | -1,185,500.00% |
| EPS Diluted | -1,046.94% | -2,567.30% | -4,077.22% | -5,391.97% | -949,050.00% |
| Normalized Diluted EPS | -245.76% | -639.99% | -876.91% | -937.12% | -1,185,500.00% |
| Average Basic Shares Outstanding | 116.45% | -99.08% | -99.20% | -99.32% | -99.38% |
| Average Diluted Shares Outstanding | 116.45% | -99.08% | -99.20% | -99.32% | -99.38% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |